• About
• Links
• Contact
• Sitemap

Immunotherapy in Allergic Rhinitis

Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion.

Scope

Detailed break-down of the prevalence of allergic rhinitis by country, severity and type of allergen

Evaluation of current strategies for the treatment of this disease, including the current role of immunotherapy

Analysis of future trends in immunotherapy

Assessment of the potential for new immunotherapies

Report Highlights
The prevalence of allergic rhinitis in the seven major markets ranges from 7.9% (Spain) to 17.2% (France), but only about half of the affected population currently seek treatment.

Immunotherapy is dominated by a few regional players, constituting a small niche within the EUR 16 billion allergic rhinitis market.

Several small companies are developing immunotherapy products with likely competitive advantages over currently available products. The aim is to achieve shorter sublingual immunotherapy courses.

Reasons to Purchase

Identify the most lucrative targets for immunotherapeutic product development strategies in allergic rhinitis

Detailed breakdown of the prevalence of allergic rhinitis according to country, severity and allergen

Gain competitive advantages when positioning new immunotherapies for allergic rhinitis

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE - page 2
  • About the Respiratory & Infectious Disease (RID) analysis team - page 2
• CHAPTER 1 EXECUTIVE SUMMARY - page 4
  • Scope - page 4
  • Datamonitor insight into the disease market - page 5
• CHAPTER 2 DISEASE BACKGROUND - page 7
  • Disease classification and epidemiology - page 7
    • Prevalence of AR - page 8
    • Historic trends in AR prevalence show increase - page 19
    • Costs of AR - page 20
  • Etiology - page 20
    • Minimal persistent inflammation - page 23
  • Symptoms and co-morbidities - page 24
    • Asthma is main and most important co-morbidity - page 25
  • Diagnosis - page 26
• CHAPTER 3 TREATMENT OPTIONS - page 28
  • Immunotherapy - page 35
  • Immunotherapy: an expanding market? - page 42
• CHAPTER 4 FUTURE TRENDS IN IMMUNOTHERAPY - page 45
  • Company overview - page 49
• CHAPTER 5 REFERENCES - page 56
  • Disclaimer - page 68


• List of Tables
• Table 1: Prevalence of nasal allergy, 20−44 age group, Europe, 1996 - page 10
• Table 2: Diagnosed allergic rhinitis prevalence and population by country, 2006, 2016 - page 12
• Table 3: Distribution of type of allergen in AR patients - page 13
• Table 4: The diagnosed AR population of over 20 years old according to severity and allergen in the seven major markets for 2006 and 2016, in millions - page 15
• Table 5: The diagnosed AR population of over 20 years old according to severity and allergen in the US for 2006 and 2016, in millions - page 16
• Table 6: The diagnosed AR population of over 20 years old according to severity and allergen in Europe for 2006 and 2016, in millions - page 17
• Table 7: The diagnosed AR population of over 20 years old according to severity and allergen in Japan for 2006 and 2016, in millions - page 18
• Table 8: Time trends in hay fever or allergic rhinitis in school age children in the UK, Finland, and Germany - page 19
• Table 9: Heredity as a risk factor for allergic rhinitis - page 20
• Table 10: Symptoms measured with a written questionnaire in children aged 13−14 years in the seven major markets - page 25
• Table 11: Allergic rhinitis treatment recommendations by ARIA (2001) - page 33
• Table 12: Novel AR immunotherapies in clinical development - page 48


• List of Figures
• Figure 1: Classification of allergic rhinitis is based on duration and severity of symptoms - page 8
• Figure 2: Age distribution of allergic rhinitis shows peak between 15 and 25 years old, Germany, 1995 - page 11
• Figure 3: Distribution of severity of diagnosed AR patients - page 12
• Figure 4: The allergic response in allergic rhinitis - page 21
• Figure 5: Triggers of allergic rhinitis include allergens, pollutants and aspirin - page 22
• Figure 6: Concept of minimal persistent inflammation - page 23
• Figure 7: Classification of the symptoms of allergic rhinitis - page 24
• Figure 8: The diagnosis of AR relies on patient history and allergen tests - page 27
• Figure 9: Treatment options in allergic rhinitis include allergen avoidance, pharmacotherapy and immunotherapy - page 29
• Figure 10: Stepwise approach to the treatment of allergic rhinitis - page 34
• Figure 11: SIT is a niche market in the AR market - page 37
• Figure 12: Three leading companies cover two-thirds of SIT market - page 38
• Figure 13: 13−38% of seasonal AR sufferers are not suitable candidates for immunotherapy - page 40
• Figure 14: Immunotherapy market in the treatment of AR has opportunity to expand - page 44
• Figure 15: Distribution of pipeline products according to Phase - page 45
• Figure 16: Distribution of pipeline products according to allergen - page 47

Other users found this report page using the following search terms: rhinitis allergic rhinitis prevalence children current trends treatment

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.